Navigation Links
NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals
Date:8/27/2007

RESEARCH TRIANGLE PARK, N.C., Aug. 27 /PRNewswire/ -- NovaQuest has made a strategic investment in TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders. The investment was part of a private placement of C$26 million (US$25 million) in the Montreal-based company.

Last week's The investment by NovaQuest, the strategic partnering group of Quintiles Transnational, helps TOPIGEN accelerate its Phase II lead-product clinical programs. NovaQuest and Quintiles first provided strategic product development advice to TOPIGEN three years ago; the relationship has since evolved into an integrated development partnership.

Patricia Lamothe, TOPIGEN's Chief Financial Officer, said: "The ability to access NovaQuest's clinical expertise and Quintiles' development capabilities is a tremendous benefit to our company as we continue to advance our product candidates for significant breakthroughs in the treatment of respiratory diseases."

NovaQuest Vice President Ben Cons, Ph.D., said: "Having been very active in 2006, with 16 strategic investments, our focus now is to create fewer but larger partnerships. We're seeking high potential biotechs -- those with excellent pipelines and strong management teams. Our managed partnership with TOPIGEN is an example of this.

"We believe that NovaQuest's strong clinical experience and intellectual capital, backed by Quintiles' global development resources, is a great fit to help TOPIGEN advance its clinical candidates efficiently and strategically."

In November NovaQuest made a strategic investment in Canadian biotech company BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis. For all of 2006, NovaQuest participated as a minority investor in funding rounds that raised a total of $342 million for 16 emerging biotechnology companies worldwide.

NovaQuest, the strategic partnering group of Quintiles Transnational, is an industry pioneer in offering tailored financial and operational solutions that help pharmaceutical and biotech companies overcome development and commercialization challenges, including leveraging "virtual clinical development" models. Its unique managed-partnership approach ensures sponsorship by senior-level executives; access to global development and commercial resources and expertise; and efficient operational delivery of services. Since 2000, NovaQuest partnerships have committed more than $2 billion in capital to pharmaceutical and biotech companies of all sizes. For more information, please visit http://www.novaquest.com.

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With 19,000 employees and offices in more than 50 countries, it is focused on providing customer- centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com.


'/>"/>
SOURCE NovaQuest
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
2. Quintessence Biosciences advances cancer drug
3. Healthcare slow to adopt genetic advances
4. Wireless advances in Madison, heats up in Waukesha
5. GE Healthcares CT Scanner advances coronary imaging
6. Cancer treatment advances as trials show no harm to mice
7. New CT scanner by GE Healthcare advances imaging technology
8. Small wonders: Intersection of biotech and nanotech will produce big advances
9. Standards Needed for Advances in Healthcare Technology
10. Virtual communities make online connections
11. Virtual-reality welding simulator an opportunity for Chippewa Valley college
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
Breaking Biology Technology:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
Breaking Biology News(10 mins):